Clinical trial
A First-in Human, Phase 1 Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors
NCT07928258 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First-in Human, Phase 1 Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- March 31, 2032
- Enrollment
- 370 (estimated)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.
Lead sponsor's other trials
Eli Lilly and Company, most recent start first.
+2,100 more trials See the organization page
Similar trials
Same condition (Endometrial Neoplasms) and phase, most recent start first.
+225 more trials See the condition page